Target
Nuclear receptor ROR-alpha
Ligand
BDBM50509340
Substrate
n/a
Meas. Tech.
ChEMBL_1837937 (CHEMBL4338070)
IC50
>10000±n/a nM
Citation
 Marcoux, DDuan, JJShi, QCherney, RJSrivastava, ASCornelius, LBatt, DGLiu, QBeaudoin-Bertrand, MWeigelt, CAKhandelwal, PVishwakrishnan, SSelvakumar, KKarmakar, AGupta, AKBasha, MRamlingam, SManjunath, NVanteru, SKarmakar, SMaddala, NVetrichelvan, MGupta, ARampulla, RAMathur, AYip, SLi, PWu, DRKhan, JRuzanov, MSack, JSWang, JYarde, MCvijic, MELi, SShuster, DJBorowski, VXie, JHMcIntyre, KWObermeier, MTFura, AStefanski, KCornelius, GHynes, JTino, JAMacor, JESalter-Cid, LDenton, RZhao, QCarter, PHDhar, TGM Rationally Designed, Conformationally Constrained Inverse Agonists of ROR?t-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy. J Med Chem 62:9931-9946 (2019) [PubMed]  Article 
Target
Name:
Nuclear receptor ROR-alpha
Synonyms:
NR1F1 | Nuclear receptor RZR-alpha | Nuclear receptor subfamily 1 group F member 1 | RAR-related orphan receptor A | RORA | RORA_HUMAN | RZRA | Retinoid-related orphan receptor-alpha
Type:
PROTEIN
Mol. Mass.:
58976.26
Organism:
Homo sapiens (Human)
Description:
ChEMBL_101591
Residue:
523
Sequence:
MESAPAAPDPAASEPGSSGADAAAGSRETPLNQESARKSEPPAPVRRQSYSSTSRGISVTKKTHTSQIEIIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQSNATYSCPRQKNCLIDRTSRNRCQHCRLQKCLAVGMSRDAVKFGRMSKKQRDSLYAEVQKHRMQQQQRDHQQQPGEAEPLTPTYNISANGLTELHDDLSNYIDGHTPEGSKADSAVSSFYLDIQPSPDQSGLDINGIKPEPICDYTPASGFFPYCSFTNGETSPTVSMAELEHLAQNISKSHLETCQYLREELQQITWQTFLQEEIENYQNKQREVMWQLCAIKITEAIQYVVEFAKRIDGFMELCQNDQIVLLKAGSLEVVFIRMCRAFDSQNNTVYFDGKYASPDVFKSLGCEDFISFVFEFGKSLCSMHLTEDEIALFSAFVLMSADRSWLQEKVKIEKLQQKIQLALQHVLQKNHREDGILTKLICKVSTLRALCGRHTEKLMAFKAIYPDIVRLHFPPLYKELFTSEFEPAMQIDG
  
Inhibitor
Name:
BDBM50509340
Synonyms:
CHEMBL4475601
Type:
Small organic molecule
Emp. Form.:
C29H27ClF7NO5S
Mol. Mass.:
670.035
SMILES:
[H][C@@]12CCc3cc(ccc3[C@@]1(CCN2C(=O)[C@H]1CC[C@@H](CC1)C(O)=O)S(=O)(=O)c1cccc(Cl)c1)C(F)(C(F)(F)F)C(F)(F)F |r,wU:16.18,wD:19.25,1.0,10.28,(39.24,-25.54,;37.91,-26.32,;37.91,-24.77,;36.57,-23.98,;35.23,-24.76,;33.89,-24,;32.56,-24.77,;32.56,-26.32,;33.89,-27.09,;35.22,-26.32,;36.56,-27.09,;36.87,-28.61,;38.42,-28.79,;39.06,-27.37,;40.57,-27.06,;41.05,-25.6,;41.59,-28.21,;43.09,-27.89,;44.11,-29.04,;43.63,-30.51,;42.12,-30.82,;41.1,-29.67,;44.65,-31.66,;44.17,-33.12,;46.16,-31.34,;35.46,-28.18,;34.36,-29.27,;33.97,-27.77,;35.84,-29.67,;34.75,-30.74,;35.13,-32.23,;36.62,-32.65,;37.72,-31.56,;39.2,-31.96,;37.33,-30.07,;31.23,-24,;29.89,-23.23,;29.89,-24.77,;28.56,-24,;29.89,-26.31,;28.55,-25.53,;31.23,-22.46,;32.56,-21.69,;29.89,-21.69,;31.22,-20.92,)|
Structure:
Search PDB for entries with ligand similarity: